Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway
Sign Up to like & getrecommendations! Published in 2021 at "Pharmaceutical Biology"
DOI: 10.1080/13880209.2021.1972122
Abstract: Abstract Context Yang-Yin-Jie-Du Decoction (YYJDD) was used to improve gefitinib efficacy in our clinical practice, but its mechanism remains unclear. Objective This study explored if YYJDD could reverse gefitinib resistance. Materials and methods H1975 cells… read more here.
Keywords: gefitinib resistance; combination; cell; pi3k akt ... See more keywords
Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance
Sign Up to like & getrecommendations! Published in 2022 at "BioMed Research International"
DOI: 10.1155/2022/5687832
Abstract: Met proto-oncogene (MET) amplification and tyrosine-protein kinase Met (c-Met) overexpression confer gefitinib resistance in non-small cell lung cancer (NSCLC). The natural product Licochalcone A (Lico A) exhibits a broad range of inhibitory effects against various… read more here.
Keywords: resistance nsclc; licochalcone; resistance; gefitinib resistance ... See more keywords
The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Mediators of Inflammation"
DOI: 10.1155/2023/9658912
Abstract: Background Gefitinib resistance remains a major problem in the treatment of lung cancer. However, the underlying mechanisms involved in gefitinib resistance are largely unclear. Methods Open-accessed data of lung cancer patients were downloaded from The… read more here.
Keywords: lung cancer; gefitinib resistance; resistance; involved gefitinib ... See more keywords
Abstract 379: Circumvention of gefitinib resistance by repurposing flunarizine via histone deacetylase inhibition in lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-379
Abstract: Introduction: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) indicated for first-line treatment of advanced non-small cell lung cancer (NSCLC) bearing the sensitizing EGFR mutations. However, drug resistance is severely hindering… read more here.
Keywords: circumvention gefitinib; gefitinib; gefitinib resistance; resistance ... See more keywords
Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-20-0541
Abstract: Gefitinib is suitable for the treatment of locally advanced or metastatic non–small cell lung cancer. However, the development of acquired resistance limits its long-term efficacy in regardless of significant clinical benefit to patients. Therefore, to… read more here.
Keywords: resistance; recipient; gefitinib resistance; gefitinib ... See more keywords
PLIN2 confers gefitinib resistance by inhibiting cell apoptosis via activation of EGFR/AKT/survivin in PC9R cells
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24153
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line drugs for advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the development of TKI resistance is a major clinical… read more here.
Keywords: akt survivin; gefitinib resistance; pc9r cells; egfr akt ... See more keywords
Identification of Gefitinib Resistance-Related lncRNA-miRNA-mRNA Regulatory Networks and Corresponding Prognostic Signature in Patients with Lung Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of General Medicine"
DOI: 10.2147/ijgm.s369718
Abstract: Purpose To identify and characterize gefitinib resistance-related (GefR-related) lncRNAs and construct a prediction model for lung adenocarcinoma (LUAD). Methods Differential expression analysis between PC9 and gefitinib-resistant PC9 (PC9GR) cell samples was performed to screen GefR-related… read more here.
Keywords: resistance related; signature; prognostic signature; gefr related ... See more keywords
Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.00062
Abstract: In this study, the mechanism of the anticancer effect through which cucurbitacin D (CuD) can overcome gefitinib resistance in NSCLC was investigated. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide assay, and cell migration and growth… read more here.
Keywords: cud; gefitinib resistance; binding egfr; resistance ... See more keywords
The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression
Sign Up to like & getrecommendations! Published in 2022 at "Acta Biochimica et Biophysica Sinica"
DOI: 10.3724/abbs.2022176
Abstract: Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),is the currently recommended first-line therapy for advanced EGFR-mutant lung cancer, and understanding the mechanism of resistance is the key to formulating therapeutic strategies for EGFR-TKIs. In… read more here.
Keywords: pseudogene duxap10; resistance nsclc; expression; gefitinib resistance ... See more keywords
MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
Sign Up to like & getrecommendations! Published in 2019 at "Molecular medicine reports"
DOI: 10.3892/mmr.2018.9710
Abstract: Epidermal growth factor receptor‑tyrosine kinase inhibitors, such as gefitinib, have been found to be clinically effective in the treatment of patients with non‑small cell lung cancer (NSCLC). However, the therapeutic effect of gefitinib is often… read more here.
Keywords: gefitinib resistance; mir 506; 9gr cells; cell ... See more keywords
TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway
Sign Up to like & getrecommendations! Published in 2023 at "Oncology Reports"
DOI: 10.3892/or.2023.8521
Abstract: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancers and remains the most common cause of cancer-related death. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have been used as first-line… read more here.
Keywords: cell; trip13; gefitinib resistance; resistance ... See more keywords